31 results about "Vascular resistance" patented technology

The invention provides a multi-source heterogeneous data integrated coronary heart disease accurate prediction method, which comprises the following steps: acquiring various physiological signals of a patient in real time, the physiological signals comprising ST segment change characteristics and basic cycle function parameters in electrocardiosignals, and obtaining a multi-source signal data set; according to the joint data set, analyzing instantaneous fluctuation characteristics of a vascular resistance index in a postprandial hyperlipemia window period, extracting a vascular resistance fluctuation amplitude from the instantaneous fluctuation characteristics, and if it is detected that the fluctuation amplitude exceeds a preset threshold range, marking the window as a high-risk time window; if the score value exceeds a preset threshold value, triggering a coronary heart disease early warning signal according to the comprehensive risk score value in combination with a feature mode of a coronary heart disease hidden period in historical data; and storing the current high-risk time window characteristics and the blood sugar and blood fat curve change trend through a triggered coronary heart disease early warning signal to obtain structured risk archive data.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention relates to the technical field of medical health, and discloses a cardiopulmonary ultrasound assessment method and system for premature infant BPD early warning. The method comprises the steps that premature infant heart rate variability, pulmonary artery systolic pressure and respirator parameter data are synchronously collected through an HL7 FHIR protocol interface, and a BPD early warning basic data set is obtained; performing weighted fusion on the ratio of SDNN to RMSSD, the square ratio of pulmonary artery to systemic circulation systolic pressure and oxygenation parameters in the data through an algorithm to obtain a CPDI value; the CPDI and the cardiopulmonary parameters are combined to evaluate the pulmonary vascular resistance load, and a PVRL index is obtained; the CPDI, the PVRL, the gestational age and the body weight adjustment factor are fused, and a BPD occurrence risk score is obtained; and dividing risk levels according to the scoring interval and generating an early warning result. According to the method, the problem that premature infant BPD early warning lacks cardiopulmonary system multi-parameter fusion analysis and individualized risk assessment in the prior art is solved, and continuous dynamic early warning and accurate risk layering based on CPDI and PVRL indexes are achieved.

The invention discloses a cerebral infarction risk early warning method and system based on an image feature change trend, and relates to the technical field of cerebral infarction early warning. The cerebral infarction risk early warning method comprises the steps of feature extraction, wherein image data and modal data are processed through a feature analysis method, and image features, image feature change data, modal data features, modal data feature change data and regions where the features are located are obtained; the image data provides visual information of a brain structure and a focus, the modal data supplements key features such as hemodynamics, brain tissue electrical activity and electrical impedance from different physiological dimensions, the TCD data can monitor blood flow velocity and vascular resistance in real time, and the BI data is sensitive to change of pathological states such as encephaledema. The EEG data reflects the subtle change of the electrical activity of neurons, and the image feature change trend is corrected through feature extraction and analysis and combination of multi-source heterogeneous data, so that the accuracy of cerebral infarction risk early warning is ensured.

An electronic device may comprise a biometric sensor and at least one processor. At least one processor may be configured to obtain a PPG signal through the biometric sensor. At least one processor may be configured to obtain a blood flow rate of a user wearing a wearable electronic device on the basis of the PPG signal. At least one processor may be configured to obtain the blood pressure of the user. At least one processor may be configured to determine cardiovascular resistance indicating a degree to which blood flow is affected in a cardiovascular system of the user based on the obtained blood flow rate and the obtained blood pressure.

The application discloses a non-invasive continuous real-time blood pressure and hemodynamics and heart function integrated device and a data calculation method thereof, which comprises a signal acquisition module, a statistical and weighted calculation module, a communication module and a display module which are electrically connected with a main control board, wherein the signal acquisition module comprises an ECG and heart sound digitization detection module and a real-time continuous blood pressure and hemodynamics calculation module.The application has the beneficial effects that: the device combines the heart sound and ECG with the non-invasive hemodynamics acquisition device, and the blood pressure parameters obtained by the device are mutually calibrated, so that the device not only solves the problems of real-time continuous blood pressure and hemodynamics detection, but also synchronously outputs ECG parameters, heart sound logarithms, cardiac output, stroke volume, vascular resistance, cardiac contractility and other parameters.

A method of determining a microvascular resistance score indicating perfusion of myocardial tissue in a body of a mammal is provided, comprising obtaining acquired blood pressure data and flow data of blood in a cardiac vessel while the mammal is in a first physiological state; obtaining throughflow data indicative of a geometry the cardiac vessel; generating adjusted blood pressure data and adjusted flow data corresponding to a second physiological state, based on the acquired blood pressure value and the first physiological state; generating the microvascular resistance score, based on the adjusted blood pressure data, the adjusted flow data and the throughflow data; and providing, through an electronic output signal, the microvascular resistance score for display on an electronic display module.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DBP) from one or more blood pressure devices, receiving a first bioimpedance from a first electrode and a second bioimpedance from a second electrode, determining a stroke volume based on a difference between the first bioimpedance and the second bioimpedance, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

The application provides application of levosulpiride in preparation of a medicine for treating pulmonary arterial hypertension, and the medicine comprises levosulpiride as an active ingredient. Through a pulmonary arterial hypertension model of a rat, the application gives an intervention treatment of levosulpiride, and the effect of levosulpiride on pulmonary vessels is determined: the levosulpiride can reduce the mean pulmonary arterial pressure of a pulmonary arterial hypertension rat, reduce pulmonary vascular resistance, and improve right ventricle and pulmonary vessel remodeling, thereby providing a strategy for developing the medicine for treating the pulmonary arterial hypertension.

Systems and apparatuses are included that are configured to determine an effectiveness of apparatus and methods used to diagnose and unblock microvascular obstruction (MVO). An infusion system blocks antegrade flow for a short time and measures vascular pressure response as an infusate is infused in stepwise fashion at increasingly higher flow rates. During the antegrade flow occlusion, calculations of a real-time vascular resistance can be obtained using a formula R(t)=(t) / Qmean(t) where: Qmean (t) is flow mean values generated by the infusion system; P(t) is a distal pressure response in a vessel generated from the infusion of the infusate; and R(t) is the calculated real-time vascular resistance using the two other known parameters.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The application relates to a coronary microcirculation vascular resistance acquisition method and system based on a layered myocardial model, which comprises the following steps: establishing a coronary vessel model from medical images; generating a side vessel for the coronary artery; regarding the coronary artery and the side vessel as main vessels, fitting and constructing an outer surface of a myocardial model according to the outlet position of the main vessels, establishing an inner surface of the myocardial model based on a similar principle to the outer surface, and ensuring that the volume of the model is the myocardial volume value; using an ellipsoid surface for layered interpolation; selecting a point P in the outermost layer and connecting the main vessel outlet to generate a microcirculation vessel; selecting a point T outside the current layer and cooperating with the nearest microcirculation vessel to generate a bifurcated microcirculation vessel; gradually advancing to the inner layer to form bifurcation and ensure the bifurcation number of each layer; and calculating the resistance value of the main vessel outlet. Compared with the prior art, the application considers the distribution of the coronary artery at various levels of the myocardium under real conditions, so that the calculated resistance value is more accurate and has the specificity of a patient.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

The application provides a non-invasive blood pressure estimation method, device, equipment, storage medium and product, and belongs to the technical field of biomedicine, wherein the method comprises the following steps: preprocessing an ECG signal and an ICG signal; generating physiological characteristic indexes, and the physiological characteristic indexes comprise conventional indexes and special indexes; determining the correlation between the conventional indexes and basic peripheral vascular resistance parameters and basic arterial compliance parameters; inputting the conventional indexes into a pre-trained machine learning model to output basic peripheral vascular resistance prediction parameters and basic arterial compliance prediction parameters; dynamically correcting the special indexes to generate target peripheral vascular resistance parameters and target arterial compliance parameters; and calculating and generating a blood pressure estimation result. The non-invasive blood pressure estimation method, device, equipment, storage medium and product provided by the application can improve the accuracy, dynamic nature and stability of non-invasive blood pressure estimation.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and / or treating the PH. Since a protein level and / or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement / right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

To provide an agent for the treatment of a patient suffering from pulmonary arterial hypertension (PAH).SOLUTION: An agent for initial triple combination therapy with macitentan, tadalafil, and selexipag for treating a patient having PAH, the agent containing macitentan, tadalafil, and selexipag, wherein the patient has, at initiation of the initial triple combination therapy, a resting mean pulmonary arterial pressure (mPAP) of about 25 mmHg or more, a mean pulmonary arterial wedge pressure (PAWP) of about 15 mmHg or less, and a pulmonary vascular resistance (PVR) of about 240 dyne sec / cm5 or more, and wherein the macitentan and the tadalafil are administered on day 1, and the selexipag is administered within 4 weeks.SELECTED DRAWING: None

Compositions for improving heart function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, provides antiglycation and signaling, which lessens or reduces cardiovascular disease by lessening or preventing atherosclerosis, plaque formation, diastolic dysfunction, systolic dysfunction, fibrosis, and hypertension, and / or by facilitating normal nitric oxide (NO) production, which dilates the arteries, reduces blood pressure and systemic vascular resistance, and increases cardiac output in humans. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function may contain a dietetically or pharmaceutically acceptable carrier and S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate.

The application relates to a method and system for obtaining coronary end microcirculation vascular resistance based on vascular growth, and the method comprises the following steps: acquiring medical images, and extracting a myocardial model and a coronary vascular model respectively; generating collateral vessels in the coronary vascular model; regarding all coronary vessels and collateral vessels as main vessels, and obtaining the position coordinates and the vascular radius; randomly selecting a point P in the myocardial model, connecting the point P with the outlet of the main vessel, and generating microcirculation vessels for each outlet of the main vessel; randomly selecting a point T in the point cloud file of the myocardial model, connecting the point T with the nearby microcirculation vessels, and generating multiple bifurcated microcirculation vessels, until the radius of all vessel outlets in the generated vascular tree is smaller than a preset vascular threshold; and calculating the resistance value of each outlet of the main vessel. Compared with the prior art, the coronary end microcirculation vascular resistance value calculated based on the reestablished microcirculation vascular model is more accurate and has the specificity of patients.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The invention, which belongs to the technical field of the medical equipment, discloses a lung transplantation post-operative cardiopulmonary capacity collaborative evaluation and adjustment system comprising a multi-parameter acquisition module, a cardiopulmonary interaction modeling module, a capacity strain test module, a haemodynamics target setting module, a treatment response prediction module and an adjustment execution module. The system quantitatively analyzes the complex relationship among the right heart function, the pulmonary vascular resistance and the pulmonary compliance through a cardiopulmonary interaction modeling engine, evaluates the tolerance of a patient to the capacity change through a capacity strain test, and formulates an individualized hemodynamic target according to a specific cardiopulmonary interaction mode of the patient. Potential influences of different intervention measures are simulated, treatment parameters are automatically adjusted, the hemodynamic stability and the oxygenation function of a lung transplantation patient are remarkably improved, and the occurrence rate of complications is reduced.

Disclosed are a blood pressure measurement system for calculating a blood pressure value by using biometric signals measured at two different regions and a blood pressure measurement method using the same. The blood pressure measurement system includes a first sensor unit for detecting a hemorheological parameter at one region of a body; a second sensor unit for detecting a hemorheological parameter and arterial pressure at another region of the body; and a control unit including a blood pressure calculation unit for calculating a blood pressure value of a region at which a first hemorheological parameter is detected, from the first hemorheological parameter detected by the first sensor unit and a second hemorheological parameter and the arterial pressure detected by the second sensor unit. The present invention relates to a blood pressure measurement system for measuring blood pressure by using a change in vascular resistivity and a blood pressure parameter, and more specifically, to a sphygmomanometer for calculating blood pressure by using vascular resistivity obtained by a hemorheological parameter detected at one region of a body and arterial pressure and a hemorheological parameter detected at another region of the body. Accordingly, it is possible to more accurately measure blood pressure of a desired blood pressure acquisition region on the basis of a hemorheological parameter variance and vascular resistivity and greatly enhance reliability of a sphygmomanometer.

The invention provides an intelligent high-pressure injector contrast agent optimization method, which comprises the following steps: partitioning a target organ region according to the contrast agent circulation time and the target organ strengthening degree, and calculating the blood vessel density, strengthening rate gradient and distribution uniformity of different partitions to obtain a partition feature set; strengthening time delay, strengthening range change amplitude and speed are extracted from the partition feature set, the strengthening rate of each partition is analyzed, a strengthening rate change trend is obtained, and scanning delay time and a trigger threshold value are determined; if the individual difference exceeds a threshold value, blood perfusion indexes and vascular resistance indexes in target organ artery blood vessels are extracted through CTA, contrast agent injection rate regulation and control parameters are adjusted in combination with scanning delay time, and a dynamic injection scheme is obtained; and generating target organ image data containing multi-phase optimization information according to the contrast ratio of the focus and the organ, the tissue strengthening uniformity index and the contrast agent utilization rate index, and obtaining a final multi-phase image display result.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

The application belongs to the field of FAM177A1 application research, and particularly relates to a new application of FAM177A1. Mainly disclosed are: application of a preparation for detecting FAM177A1 in preparation of a detection product for a myocardial cell hypertrophy disease; application of FAM177A1 or an expression promoter thereof in preparation of a medicine for treating the myocardial cell hypertrophy disease; application of FAM177A1 in preparation of a medicine for treating a disease induced by activation of a MAPK / ERK channel; and application of FAM177A1 in preparation of an inhibitor for non-diagnostic treatment activity of a MAPK enzyme. In the application, FAM177A1 has an inhibiting effect on MAPK, FAM177A1 can become a target for resisting cardiac hypertrophy, so as to prevent or treat occurrence and development of cardiac hypertrophy; and FAM177A1 can also be used as a product for diagnosing and treating cardiac hypertrophy caused by peripheral vascular resistance such as aortic arch constriction and hypertension.

This invention relates to a wearable multimodal hemodynamic monitoring device and method, belonging to the field of biotechnology and medicine. The device uses fewer sensors to acquire a greater number of multimodal physiological signals at fewer points on the human body. After signal processing and parameter calculation, it can continuously and synchronously monitor hemodynamic parameters including blood flow, blood pressure, and vascular resistance. Compared with existing technologies, this invention has advantages such as comprehensive measurement parameters, portable device, long battery life, and good human-computer interaction. It can be used for long-term, real-time hemodynamic monitoring and has significant application value and broad application prospects in cardiovascular disease diagnosis, chronic disease management, and exercise assessment.

The invention discloses an intelligent hemodynamics simulation platform based on deep learning, and relates to the technical field of medical instruments. The platform comprises a blood flow simulation device, a control system and a secondary bypass device, the blood flow simulation device is used for simulating a left descending branch artery and comprises a blood vessel pipeline, and a constant-temperature water tank for simulating blood supply in a human body temperature environment, a first motor for simulating a bridge blood vessel extrusion scene and a first pressure regulating valve for simulating myocardial bridge far-end vascular resistance which are sequentially arranged on the blood vessel pipeline; the secondary bypass device is used for simulating a coronary artery bypass transplantation CABG branch so as to bypass a myocardial bridge extrusion part and recover blood supply of ischemic myocardium; and the second-stage bypass device comprises a first water pump, a first compliance chamber and a second pressure regulating valve which are connected in sequence. The control system is integrated with a deep learning model, and driving signals of all parts of the simulation platform are generated through the deep learning model. According to the simulation platform, accurate simulation of treatment intervention of coronary artery bypass grafting (CABG) is realized.